Blood Coagulation Disorders
Hemorrhagic and thrombotic disorders that occur as a consequence of abnormalities in blood coagulation due to a variety of factors such as COAGULATION PROTEIN DISORDERS; BLOOD PLATELET DISORDERS; BLOOD PROTEIN DISORDERS or nutritional conditions.
Subtype terms (10)
More specific conditions that are subtypes of Blood Coagulation Disorders in the MeSH hierarchy.
- Blood Coagulation Disorders, Inherited
1 drug experimental
- Coagulation Protein Disorders
5 drugs (4 approved, 1 experimental)
- Disseminated Intravascular Coagulation
12 drugs (10 approved, 2 experimental)
- Ecchymosis
11 drugs (9 approved, 2 experimental)
- Platelet Storage Pool Deficiency
6 drugs approved
- Protein S Deficiency
2 drugs approved
- Purpura
60 drugs (38 approved, 22 experimental)
- Thrombocythemia, Essential
75 drugs (45 approved, 30 experimental)
- Thromboinflammation
- Vitamin K Deficiency
5 drugs (3 approved, 2 experimental)
Drugs by status
Approved for this indication (2)
Phase 4 trials (14)
Phase 3 trials (1)
Phase 2 trials (7)
Phase 1 trials (4)
Organizations
Organization Involved with Phase 4 Indications (28)
- CSL Behring
- Novo Nordisk
- Harvard University
- Florida International University
- NHS Lothian
- University of Edinburgh
- University of Florida
- University of Iowa
- University of Ottawa
- Wake Forest University
- University of Zurich
- Capital Medical University
- Dalian Medical University
- University of Chicago
- University of Copenhagen
- University of Turku
- Zhejiang University
- Jean Monnet University
- Adolphe Rothschild Ophtalmologic Foundation
- University of Toulouse
- University of Sao Paulo
- Mountain States Regional Hemophilia Center, Aurora, Columbia
- Department of Health and Human Services
- Canadian Hemophilia Society
- Government of Canada
- University of Helsinki
- Society for Obstetric Anesthesia and Perinatology
- Government of Nova Scotia
Organization Involved with Phase 3 Indications (52)
- Bayer
- Direction Centrale du Service de Santé des Armées
- National Heart, Lung, and Blood Institute (NHLBI)
- Unity Health Toronto
- University of Pittsburgh
- Federal University of Bahia
- University of Washington
- French Defence Health Service
- Johns Hopkins University
- McMaster University
- Medical University Innsbruck
- Monash University
- Rutgers University
- Thomas Jefferson University
- University of Oregon
- University of Toronto
- Wayne State University
- University of Vermont
- Austin Health
- University of Modena and Reggio Emilia
- Fire Brigade Of Paris
- Icahn School of Medicine at Mount Sinai
- Institut de Recherche Biomedicale des Armees
- University of Minnesota
- CHU Henri Mondor
- University of Lille
- Hebrew University
- Pharmaceutical Research Associates, Inc. (PRA)
- University of Lyon
- Asahi Kasei Pharma
- +22 more
Organization Involved with Phase 2 Indications (17)
- Biomarin
- Catalyst Biosciences
- Instituto Bioclon
- Gilead Sciences
- Novartis
- Spark Therapeutics
- Entegrion, Inc.
- Aarhus University
- University of Pennsylvania
- University of Arizona
- Temple University
- Oriental Neurosurgery Evidence-Based-Study Team
- Yale University
- Assiut University
- Medical University of Vienna
- Ono Pharmaceuticals
- Celularity, Inc.
Organization Involved with Phase 1 Indications (7)
Organization Involved with Other Experimental Indications (12)
- Abbott
- Cornell University
- Eastern Virginia Medical School
- Mary M. Gooley Hemophilia Center
- Seoul National University
- University of Pretoria
- University of Bern
- Institute of Liver and Biliary Sciences, India
- University of Strasbourg
- American College of Obstetricians and Gynecologists
- Centers for Disease Control and Prevention (CDC)
- Hospital Regional de Alta especialidad de Ixtapaluca